In:
British Journal of Haematology, Wiley, Vol. 166, No. 1 ( 2014-07), p. 98-108
Kurzfassung:
Mantle cell lymphoma ( MCL ) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL 2/3 protocols. In 2008, a MCL international prognostic index ( MIPI ) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment‐related morbidity, additional parameters need to be evaluated to enable risk‐adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX 11, TP 53 (p53), MKI 67 (Ki‐67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX 11 was shown to significantly add prognostic information to the MIPI , but in multivariate analysis TP 53 was the only significant independent molecular marker. Based on these findings, we propose that TP 53 and SOX 11 should routinely be assessed and that a combined TP 53/ MIPI score may be used to guide treatment decisions.
Materialart:
Online-Ressource
ISSN:
0007-1048
,
1365-2141
DOI:
10.1111/bjh.2014.166.issue-1
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2014
ZDB Id:
1475751-5
